Moran Eye Center seeks to understand, prevent retinopathy of prematurity

Article

A new study shows major progress toward isolating the causes of ROP.

 

Salt Lake City-A new study published by The University of Utah’s John A. Moran Eye Center shows major progress toward isolating the underlying causes of retinopathy of prematurity (ROP).

Researchers are closer to suppressing effects from specific cells that overproduce vascular endothelial growth factor (VEGF), but also other organs in human infants, including the brain, kidney, and lungs. Overproduction of VEGF could lead to blindness in pre-term infants.

The study, which is published in the September issue of the American Journal of Pathology, also uses rats, not mice, in a more representative study model of human ROP in pre-term infants. But it proposes modifying the rat oxygen-induced retinopathy (OIR) model using gene delivery approaches which will allow researchers to regulate the production of VEGF to combat ROP without negatively compromising other prenatal growth.

Because studying fragile human preterm infant eyes to understand ROP is unsafe, researchers typically use a mouse model of OIR to examine the production of VEGF and for the development of treatment options. Using a rat OIR model is actually more representative of human ROP, but using this model requires pharmacological manipulations that do not determine specific cells that overproduce VEGF or how VEGF causes growth of abnormal, instead of normal, blood vessels. Use of molecular methods improves the rigor of the model and also targets pathologic pathways while sparing normal pathways.

This study was funded by the National Eye Institute (grant EY015130).

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD, and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.
© 2025 MJH Life Sciences

All rights reserved.